Integrated multi-biomarker panel of CXCL13, HS-CRP, and WBC counts predicts outcomes in stroke neurosyphilis patients treated with HBO and TUS-NMES.

BACKGROUND

Neurosyphilis results from invading the central nervous system, leading to severe neurological issues like stroke. Combining hyperbaric oxygen (HBO) therapy and transcranial ultrasound neuromuscular stimulation (TUS-NMES) shows promise in improving outcomes.

OBJECTIVE

This study evaluates the predictive value and clinical significance of CXCL13, WBC, and Hs-CRP levels in neurosyphilis patients undergoing HBO and TUS-NMES therapy.

METHODS

The study included 158 neurosyphilis stroke patients treated from June 2022 to January 2024. Assessments of limb motor, cognitive functions, daily living abilities, and cerebrospinal fluid biomarkers were conducted pre- and post-four weeks of combined therapy.

RESULTS

After treatment, there was a significant improvement in FMA, MoCA, and MBI scores ( < 0.001). CXCL13 levels significantly decreased post-treatment, correlating with improved patient outcomes. The study found strong predictive values for CXCL13 levels in determining the efficacy of rehabilitation, with the combination of CXCL13, WBC, and Hs-CRP showing the highest predictive accuracy.

CONCLUSION

HBO and TUS-NMES significantly enhance recovery in neurosyphilis stroke patients. CXCL13, WBC, and Hs-CRP effectively predict rehabilitation outcomes, highlighting their value in clinical management.